Hypertension management guidelines (adult)
The most commonly cited current guidance for outpatient hypertension management is from the 2017 ACC/AHA guideline (United States) [1], the 2024 ESC guideline update for “elevated blood pressure and hypertension” (Europe) [2], the 2020 ISH global hypertension practice guidelines [3], and the 2022 WHO pharmacologic treatment guideline for hypertension in adults [4].
Blood pressure confirmation and definition
Confirmed hypertension is diagnosed using properly measured office blood pressure with appropriate technique and repeat measurements per guideline workflows [1], with additional reliance on out-of-office BP assessment emphasized in ESC guidance [2].
Treatment initiation thresholds
ACC/AHA (United States, 2017):
- Antihypertensive medication is recommended for adults with confirmed stage 2 hypertension (≥140 or ≥90 mmHg) [1].
- Antihypertensive medication is also recommended for adults with stage 1 hypertension (130–139 or 80–89 mmHg) when elevated cardiovascular disease (CVD) risk is present, with lifestyle therapy for low-risk stage 1 hypertension [1].
ESC (Europe, 2024):
- The ESC guideline update introduces a new systolic treatment target framework and stresses that treatment targets require good tolerability and that less intensive targets may be used in selected circumstances [2].
WHO (global, 2022):
- The WHO pharmacologic guideline provides recommendations on when to start drug therapy and how to intensify treatment, based on global evidence syntheses [4].
Target blood pressure goals
ACC/AHA (United States, 2017):
- A goal of <130/80 mmHg is recommended for most adults with hypertension [1].
ESC (Europe, 2024):
- For most patients receiving antihypertensive medication, the recommended systolic target range is 120–129 mmHg (with tolerability requirements) [2].
- The ESC also documents an overall target structure presented as 120–129/70–79 mmHg for many patients, contingent on treatment tolerability [2].
Medication selection algorithm
Core first-line drug classes across major guidelines:
- Thiazide-type diuretics (for example, chlorthalidone, indapamide, or hydrochlorothiazide) [4].
- ACE inhibitors or ARBs (for example, lisinopril or losartan) [4].
- Long-acting dihydropyridine calcium channel blockers (for example, amlodipine) [4].
Use-when-specific conditions framework (principle):
- Selection is individualized based on comorbidities, adverse effect profiles, kidney function, and drug–drug interaction risk as emphasized in guideline treatment chapters and summaries [1], [2].
Monotherapy versus combination therapy
ACC/AHA (2017):
- Two-drug therapy is recommended when initial BP is substantially above goal, because combination therapy improves the likelihood of reaching target BP [1].
- Independent initiation of lifestyle therapy is recommended for all patients in parallel with drug therapy when indicated [1].
WHO (2022):
- Combination therapy is addressed using an evidence-based approach that centers on a small set of foundational classes and structured intensification [4].
Treatment intensification and follow-up
Longitudinal management is structured around measurement-driven titration and reassessment of target attainment, adverse effects, and adherence, consistent with major guideline follow-up workflows [1], [2].
Common pitfalls to avoid
- Under-confirmation of BP status using improper technique or inadequate repeat/confirmed measurement is discouraged by guideline measurement standards [1], [2].
- Treating to intensive targets without regard to tolerability is specifically constrained in ESC 2024 target recommendations [2].